The vaccine market continues to witness strong expansion as governments, healthcare organizations, and pharmaceutical companies intensify efforts toward disease prevention and immunization programs worldwide. The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. Increasing investment in research and development activities, along with the rising focus of sponsors and investigators on reducing research costs, is significantly contributing to market growth. Growing awareness regarding preventive healthcare, rising vaccination coverage across emerging economies, and the increasing burden of infectious diseases are also creating favorable conditions for the expansion of the vaccine industry over the forecast period.

Another major factor accelerating market growth is the increasing adoption of outsourcing laboratory services by pharmaceutical and biotechnology companies to reduce the overall cost of research activities. Outsourcing enables organizations to improve operational efficiency, accelerate vaccine development timelines, and access advanced technological capabilities without heavy infrastructure investments. The market is also benefiting from advancements in vaccine technologies such as mRNA platforms, recombinant vaccines, and viral vector vaccines, which have transformed modern immunization strategies. In addition, rising government funding, strategic collaborations among vaccine manufacturers, and expanding public-private partnerships are supporting the commercialization of innovative vaccines and strengthening the overall market landscape globally.

Download a free sample copy of the Vaccine market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         North America dominated the global market with a share of 39.80% in 2025. The region’s dominance is attributed to advanced healthcare infrastructure, strong presence of leading pharmaceutical companies, and increased investments in vaccine research and development. High awareness regarding immunization programs and favorable regulatory support further contribute to regional market growth.

·         By indication, the viral diseases segment held the largest market share of 61.17% in 2025. The increasing prevalence of viral infections and rising demand for preventive immunization against diseases such as influenza, COVID-19, hepatitis, and HPV continue to drive segment expansion. Government-led vaccination initiatives and large-scale immunization campaigns are also supporting growth within this segment.

·         By type, the subunit vaccine segment held the largest market share of 30.72% in 2025. Subunit vaccines are gaining popularity due to their improved safety profiles, targeted immune response, and reduced risk of adverse reactions compared to traditional vaccine technologies. Increasing adoption of recombinant protein-based vaccines further supports the segment’s growth trajectory.

·         By route of administration, the parenteral segment dominated the market with a share of 84.80% in 2025. The widespread use of injectable vaccines for routine immunization programs and rapid immune response capabilities contribute to the dominance of this segment. Rising healthcare access and increasing vaccination drives across developing economies further support market demand.

·         By age group, the adult segment dominated the market with a share of 56.65% in 2025. Increasing awareness regarding adult immunization, growing prevalence of chronic diseases, and rising focus on preventive healthcare are key factors driving growth in this segment. Demand for influenza, shingles, pneumococcal, and COVID-19 vaccines among adult populations continues to rise globally.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

Serum Institute of India Pvt. Ltd. holds a prominent position in the market through large scale manufacturing capabilities, cost efficient production, and a broad portfolio spanning pediatric, influenza, and COVID-19 vaccines. Seqirus and Sanofi maintain notable market presence supported by specialized expertise in influenza vaccines, established global distribution networks, and continued investments in vaccine development. Merck & Co., Inc. and Pfizer Inc. maintain substantial market shares driven by extensive vaccine pipelines, advanced R&D capabilities, and long-standing experience in complex and combination vaccines. Moderna Inc. and BioNTech SE expanded their market footprint by leveraging mRNA platform technologies and rapid clinical development capabilities. Sinovac and AstraZeneca contribute to market expansion through inactivated and viral vector vaccine platforms, broad international reach, and collaborations that improve vaccine access across diverse regions.

Key Vaccine Companies:

·        Serum Institute of India Pvt. Ltd.

·        Seqirus

·        Sanofi

·        Merck & Co., Inc.

·        Pfizer Inc.

·        Moderna Inc.

·        Sinovac

·        BioNTech SE

·        AstraZeneca

Explore Grand View Horizon to see global and regional level statistics related to the Vaccine Market

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering